Does tetrapeptide AcSDKP induce postischemic neovascularization through monocyte chemoattractant protein-1 signaling?
AcSDKP stimulates postischemic neovascularization through activation of a proinflammatory MCP-1-related pathway.
The results of the present study indicate that inhibition of the AT(1) receptor in patients with atherosclerosis reverses endothelial dysfunction by improving NO availability and therefore may have long-term therapeutic benefits.